Bausch + Lomb Co. (NYSE:BLCO) Stake Reduced by Clark Estates Inc. NY

Clark Estates Inc. NY lessened its stake in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 600,000 shares of the company's stock after selling 87,500 shares during the quarter. Bausch + Lomb makes up approximately 2.1% of Clark Estates Inc. NY's holdings, making the stock its 12th largest holding. Clark Estates Inc. NY owned 0.17% of Bausch + Lomb worth $10,836,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BLCO. Blue Trust Inc. increased its position in Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after purchasing an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Bausch + Lomb in the 4th quarter valued at about $72,000. Gordian Capital Singapore Pte Ltd purchased a new stake in Bausch + Lomb in the 3rd quarter valued at about $289,000. Polar Asset Management Partners Inc. purchased a new stake in Bausch + Lomb in the 3rd quarter valued at about $289,000. Finally, Verition Fund Management LLC purchased a new stake in Bausch + Lomb in the 3rd quarter valued at about $302,000. Hedge funds and other institutional investors own 11.07% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on BLCO. HC Wainwright restated a "buy" rating and issued a $23.00 price target on shares of Bausch + Lomb in a report on Tuesday, February 18th. Stifel Nicolaus lowered their price target on Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating for the company in a report on Wednesday, January 29th. Wells Fargo & Company lowered their price target on Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Thursday, January 16th. Citigroup cut Bausch + Lomb from a "buy" rating to a "neutral" rating and lowered their price target for the company from $24.00 to $22.00 in a report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $20.00.

Remove Ads

Bausch + Lomb Stock Up 0.8 %

Shares of BLCO traded up $0.14 during trading on Friday, reaching $16.13. The company's stock had a trading volume of 616,057 shares, compared to its average volume of 658,951. The company has a fifty day moving average of $16.95 and a two-hundred day moving average of $18.14. Bausch + Lomb Co. has a twelve month low of $13.16 and a twelve month high of $21.69. The company has a market cap of $5.68 billion, a price-to-earnings ratio of -17.72, a P/E/G ratio of 0.85 and a beta of 0.49. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last announced its earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same period in the prior year, the company posted $0.24 EPS. Bausch + Lomb's quarterly revenue was up 9.1% on a year-over-year basis. On average, sell-side analysts predict that Bausch + Lomb Co. will post 0.74 EPS for the current fiscal year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.